Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose...

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Vitamin D may modulate mucosal immune function to reduce Crohn's disease (CD) activity.
• Investigating the impact of high-dose vitamin D and infliximab on mucosal cytokine expression in active CD.

Purpose of the Study:

• To determine if high-dose vitamin D, alone or combined with infliximab, affects mucosal cytokine expression in active Crohn's disease.
• To assess the clinical efficacy of vitamin D and infliximab combination therapy.

Main Methods:

• Randomized trial of 40 CD patients into four groups: infliximab + vitamin D, infliximab + placebo, placebo + vitamin D, or placebo + placebo.
• Administration of infliximab (5 mg/kg) or placebo at weeks 0, 2, and 6; oral vitamin D (200,000 IU bolus then 20,000 IU/day) or placebo for 7 weeks.
• Endoscopic assessment, mucosal mRNA cytokine expression analysis (IL17A, IFNγ, IL10), C-reactive protein (CRP), fecal calprotectin, and Harvey-Bradshaw Index (HBI) measurements.

Main Results:

• High-dose vitamin D, as monotherapy or combined with infliximab, decreased IL17A, IFNγ, and IL10 expression.
• Vitamin D monotherapy did not significantly reduce disease activity, CRP, or fecal calprotectin levels.
• Combination therapy with infliximab and vitamin D was not significantly superior to infliximab monotherapy in clinical outcomes.

Conclusions:

• High-dose vitamin D therapy, alone or with infliximab, reduces specific mucosal cytokine expressions (IL17A, IFNγ, IL10) in Crohn's disease.
• This modulation of cytokine expression did not translate to a statistically significant decrease in overall disease activity.
• Further research may be needed to clarify the clinical role of vitamin D in managing Crohn's disease, especially in combination with biologics.